Fosfomycin dosing regimens
AssigneeMeitheal Pharmaceuticals, Inc.
InventorEvelyn Ellis-Grosse
Life of this patent
Estimating the term…
Abstract
Methods for identification of new dosing strategies which optimize positive treatment outcomes and patient safety. Specifically, new dosing strategies for fosfomycin and pharmaceutically acceptable salt thereof which have improved treatment outcomes in mammals. For example, a method of treating mammals having a bacterial infection with fosfomycin or a pharmaceutically acceptable salt thereof using improved dosing regimens.
Claims10
A dosing regimen for administering fosfomycin or a pharmaceutically acceptable salt thereof to a renally impaired patient in need of treatment wherein said renally impaired patient has an estimated creatinine clearance of between 41-50 mL/min comprising administering a first dose of 6 grams of fosfomycin or a pharmaceutically acceptable salt thereof followed by a second dose of 4 grams intravenously every 8 hours.
A dosing regimen for administering fosfomycin or a pharmaceutically acceptable salt thereof to a renally impaired patient in need of treatment wherein said renally impaired patient has an estimated creatinine clearance of between 31-40 mL/min comprising administering a first dose of 6 grams of fosfomycin or a pharmaceutically acceptable salt thereof intravenously and a second dose of 3 grams of fosfomycin or a pharmaceutically acceptable salt thereof intravenously every 8 hours.
A dosing regimen for administering fosfomycin or a pharmaceutically acceptable salt thereof to a renally impaired patient in need of treatment wherein said renally impaired patient has an estimated creatinine clearance of between 21-30 mL/min comprising administering a first dose of 6 grams of fosfomycin or a pharmaceutically acceptable salt thereof intravenously and a second dose of 5 grams of fosfomycin or a pharmaceutically acceptable salt thereof intravenously every 24 hours.
A dosing regimen for administering fosfomycin or a pharmaceutically acceptable salt thereof to a renally impaired patient in need of treatment wherein the renally impaired patient is diagnosed with a cUTI and has an estimated creatinine clearance of between 11-20 mL/min, the dosing regimen comprising administering to the patent a first dose of 6 grams of fosfomycin or a pharmaceutically acceptable salt thereof intravenously, followed by a second administration of 3 grams of fosfomycin or a pharmaceutically acceptable salt thereof intravenously every 24 hours.
A dosing regimen for administering fosfomycin or a pharmaceutically acceptable salt thereof to a renally impaired patient in need of treatment wherein said renally impaired patient has an estimated creatinine clearance selected from the group consisting of 41-50 mL/min, 31-40 mL/min, 21-30 mL/min and 11-20 mL/min, wherein the dosing regimen comprises administering a first dose of 6 grams of fosfomycin or a pharmaceutically acceptable salt thereof followed by a second dose of 4 grams intravenously every 8 hours for the patient having the estimated creatinine clearance of 41-50 mL/min, a first dose of 6 grams of fosfomycin or a pharmaceutically acceptable salt thereof intravenously and a second dose of 3 grams of fosfomycin or a pharmaceutically acceptable salt thereof intravenously every 8 hours for the patient having the estimated creatinine clearance of 31-40 mL/min, a first dose of 6 grams of fosfomycin or a pharmaceutically acceptable salt thereof intravenously and a second dose of 5 grams of fosfomycin or a pharmaceutically acceptable salt thereof intravenously every 24 hours for the patient having the estimated creatinine clearance of 21-30 mL/min and a first dose of 6 grams of fosfomycin or a pharmaceutically acceptable salt thereof intravenously and a second dose of 3 grams of fosfomycin or a pharmaceutically acceptable salt thereof intravenously every 24 hours for the patient having the estimated creatinine clearance of 11-20 mL/min.
Dependencies are inferred from the claim text.